ESMO Media Releases

An international group of researchers has found that antibodies to the human papilloma virus type 16 develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, and their presence indicates a strong increased risk of the disease.

ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO Congress 2021 will take place from 17 to 21 September 2021 at the Paris Expo Porte de Versailles, France.

De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised

Breast cancer in young women is characterised by more aggressive biological features as compared to those arising in older patients

Therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care is the reminder issued by Prof Giuseppe Curigliano

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer

Continuous chemotherapy shows greater benefit in patients with advanced breast cancer

Innovative breast cancer treatment will be discussed during the first ESMO Breast Cancer Congress in Berlin

Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress 2019.

Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)

Shortages of essential cancer medicines have a direct impact on patient care across Europe.

The newly established 2019 ESMO Breast Cancer Award will be delivered in connection with the inaugural ESMO Breast Cancer Congress